FDA Approvals in NSCLC and Soft Tissue Sarcoma, Priority Review in Bladder Cancer, and More
1 Lượt xem
• 07/18/23
0
0
Nhúng
administrator
Người đăng ký
Justin Gallagher reports two FDA approvals for immunotherapy in lung cancer, an approval in soft tissue sarcoma, a priority review designation in bladder cancer, an updated indication for a drug in prostate cancer, encouraging phase III results in bladder cancer, noninferiority findings in multiple myeloma, and a European approval in pancreatic cancer.
Cho xem nhiều hơn
Bình luận trên Facebook
SORT BY-
Nhận xét hàng đầu
-
Bình luận mới nhất